Cyclopharm (ASX:CYC) Net Loan

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:CYC Cyclopharm Ltd ASX:CYC
40 GF Score
Price A$0.60
GF Value A$0.83
Valuation Modestly Undervalued
! 7 Warning Signs
View Full Analysis

What is Cyclopharm Net Loan?

Net Loan only applies to banks and insurance companies.

ASX:CYC
40GF Score
Cyclopharm Ltd ASX:CYC
Net Loan is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Cyclopharm (ASX:CYC) Overvalued in 2026?

Based on GuruFocus' analysis, Cyclopharm stock appears to be undervalued. The current stock price of A$0.60 is trading 27.7% below its estimated GF Value™ of A$0.83. GuruFocus considers Cyclopharm to be Modestly Undervalued.

Key valuation signals for ASX:CYC:

  • Net Loan:
  • GF Value™: A$0.83 vs. price of A$0.60 (27.7% below fair value)
  • GF Score™: 40/100 with 7 warning signs

No single metric tells the full story. See the ASX:CYC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cyclopharm Business Description

Address 1 The Crescent, Unit 4, Kingsgrove, Sydney, NSW, AUS, 2208
Cyclopharm Ltd is a health technology company offering solutions related to functional lung ventilation imaging. Its proprietary product Technegas is a broad-spectrum diagnostic lung imaging technology product for the visualisation of pulmonary ventilation and lung function. The company sells its products to healthcare institutions and medical professionals. Maximum revenue is generated from its Technegas products and services, which include the sale of diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism and other respiratory conditions. Geographically, the company generates maximum revenue from its business in Europe, and the rest from Asia Pacific, Canada, the USA, and other regions.
40GF Score

Get the complete analysis for ASX:CYC

Net Loan is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.60
Price
A$0.83
GF Value